Condition (MeSH)
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
ClinicalTrials.gov lists 12 trials for Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 3 |
| 2015 | 2 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 6 |
How many Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Completed | 9 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 2 |
| AstraZeneca | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| E-cigarette | 1 |
| Budesonide and formoterol bid | 1 |
| Blood Test | 1 |
| CHOLECALCIFEROL | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap. | International journal of chronic obstructive pulmonary disease | 2020 | Yes |
| Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene. | Chest | 2020 | Yes |
| Current situation of asthma-COPD overlap in Chinese patients older than 40 years with airflow limitation: a multicenter, cross-sectional, non-interventional study. | Therapeutic advances in respiratory disease | 2020 | Yes |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.